# Novo Nordisk invests $4.1B to expand Ozempic production in Clayton, NC

Novo Nordisk announced plans to invest about $4.1 billion to expand production capability for its GLP-1 drug Ozempic at its Clayton, North Carolina facility. Construction is already underway on the 56-acre site, with about 2,000 external contractors expected at peak.

- Type: Expansion
- Announced: 2022-07-17
- Where: Clayton, North Carolina, United States
- Value: $4.10B
- Status: under construction
- Products: Ozempic (GLP-1 drug)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novo Nordisk](https://endata.com/companies/17868.md)

## Sources

- [uspublicworks.com](https://uspublicworks.com/billion-dollar-projects/), 2022-07-17: "Novo Nordisk announced plans to invest about $4.1 billion to expand their production capability to manufacture more of their GLP-1 drug 'Ozempic' at their Clayton North Carolina facility."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.